These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 781562)

  • 1. Immunologic mechanisms in cystic fibrosis.
    Nutr Rev; 1976 Jul; 34(7):210-1. PubMed ID: 781562
    [No Abstract]   [Full Text] [Related]  

  • 2. Nutrition and immunity in cystic fibrosis.
    Raeburn JA
    Proc Nutr Soc; 1977 May; 36(1):77-83. PubMed ID: 331336
    [No Abstract]   [Full Text] [Related]  

  • 3. The local immune status in cystic fibrosis.
    Pryjma J; Rudnik J; Zebrak J; Herman T; Gaweł J
    Monogr Paediatr; 1979; 10():125-30. PubMed ID: 460268
    [No Abstract]   [Full Text] [Related]  

  • 4. Cell-mediated immunity in patients with cystic fibrosis.
    Gibbons A; Allan JD; Holzel A; McFarlane H
    Br Med J; 1976 Jan; 1(6002):120-2. PubMed ID: 813805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The immunoevasive activities of Pseudomonas aeruginosa. Relevance for cystic fibrosis.
    Buret A; Cripps AW
    Am Rev Respir Dis; 1993 Sep; 148(3):793-805. PubMed ID: 8368651
    [No Abstract]   [Full Text] [Related]  

  • 6. Cell-mediated immunity on secretory surfaces.
    Wadmant RH; Gadol N; Spencer C; Johnson JE
    J Natl Med Assoc; 1972 May; 64(3):250-1. PubMed ID: 5035724
    [No Abstract]   [Full Text] [Related]  

  • 7. [Review on opportunistic infection].
    Ozawa A
    Nihon Saikingaku Zasshi; 1982 Jul; 37(4):739-56. PubMed ID: 6757471
    [No Abstract]   [Full Text] [Related]  

  • 8. Lung defense mechanisms (second of two parts).
    Newhouse M; Sanchis J; Bienenstock J
    N Engl J Med; 1976 Nov; 295(19):1045-52. PubMed ID: 787791
    [No Abstract]   [Full Text] [Related]  

  • 9. Mucosal immunity to Pseudomonas aeruginosa alginate in cystic fibrosis.
    Pedersen SS; Møller H; Espersen F; Sørensen CH; Jensen T; Høiby N
    APMIS; 1992 Apr; 100(4):326-34. PubMed ID: 1581041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hereditary disorders of local protection in the development of chronic nonspecific lung diseases].
    Didkovskiĭ NA; Dvoretskiĭ LI
    Klin Med (Mosk); 1986 Feb; 64(2):32-9. PubMed ID: 3517479
    [No Abstract]   [Full Text] [Related]  

  • 11. Defense mechanisms against infectious diseases: general considerations with particular reference to morphological and cellular aspects.
    Hess MW; Keller HU; Schädeli J; Schaffner T; Cottier H
    Monogr Allergy; 1975; 9():1-12. PubMed ID: 47142
    [No Abstract]   [Full Text] [Related]  

  • 12. Lipopolysaccharide is present in immune complexes isolated from sputum in patients with cystic fibrosis and chronic Pseudomonas aeruginosa lung infection.
    Kronborg G; Shand GH; Fomsgaard A; Høiby N
    APMIS; 1992 Feb; 100(2):175-80. PubMed ID: 1554493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The immunoglobulin G subclass composition of immune complexes in cystic fibrosis. Implications for the pathogenesis of the Pseudomonas lung lesion.
    Hornick DB; Fick RB
    J Clin Invest; 1990 Oct; 86(4):1285-92. PubMed ID: 2120286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immunopathogenic processes in infectious pulmonary diseases].
    Păunescu E
    Rev Ig Med Muncii Med Soc Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Pneumoftiziol; 1990; 39(1):5-14. PubMed ID: 2223722
    [No Abstract]   [Full Text] [Related]  

  • 15. Pulmonary host defense mechanisms.
    Harada RN; Repine JE
    Chest; 1985 Feb; 87(2):247-52. PubMed ID: 3881229
    [No Abstract]   [Full Text] [Related]  

  • 16. Pulmonary infection in cystic fibrosis: current status.
    J Pediatr; 1986 May; 108(5 Pt 2):795-870. PubMed ID: 3701532
    [No Abstract]   [Full Text] [Related]  

  • 17. The innate immune system in cystic fibrosis lung disease.
    Bals R; Weiner DJ; Wilson JM
    J Clin Invest; 1999 Feb; 103(3):303-7. PubMed ID: 9927489
    [No Abstract]   [Full Text] [Related]  

  • 18. Rationale for development of immunotherapies that target mucoid Pseudomonas aeruginosa infection in cystic fibrosis patients.
    Pier GB
    Behring Inst Mitt; 1997 Feb; (98):350-60. PubMed ID: 9382760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pediatric cystic fibrosis lung disease.
    Liu G; Li Z; Wu H
    Minerva Pediatr; 2017 Oct; 69(5):459-460. PubMed ID: 28471146
    [No Abstract]   [Full Text] [Related]  

  • 20. Harnessing Neutrophil Survival Mechanisms during Chronic Infection by
    Marteyn BS; Burgel PR; Meijer L; Witko-Sarsat V
    Front Cell Infect Microbiol; 2017; 7():243. PubMed ID: 28713772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.